Circulating Endothelial Progenitor Cells in Patients with Established Cardiovascular Disease Treated with PCSK9 Monoclonal Antibodies

IF 4.3 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Chen Gurevitz , Osnat Itzhaki Ben Zadok , Dorit Leshem-Lev , Lital Hodeda , Aviad Rotholz , Ran Kornowski , Alon Eisen
{"title":"Circulating Endothelial Progenitor Cells in Patients with Established Cardiovascular Disease Treated with PCSK9 Monoclonal Antibodies","authors":"Chen Gurevitz ,&nbsp;Osnat Itzhaki Ben Zadok ,&nbsp;Dorit Leshem-Lev ,&nbsp;Lital Hodeda ,&nbsp;Aviad Rotholz ,&nbsp;Ran Kornowski ,&nbsp;Alon Eisen","doi":"10.1016/j.ajpc.2024.100896","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The role of circulating endothelial progenitor cells (cEPCs) in vascular repair and their association to cardiovascular protection is well established.</div></div><div><h3>Objectives</h3><div>We examined the effect of proprotein convertase subtilisin kexin type 9 monoclonal antibodies (PCSK9 mAb) on cEPCs in adults with hypercholesterolemia and cardiovascular disease, aiming to establish a pleotropic class effect.</div></div><div><h3>Methods</h3><div>Non-interventional prospective study in patients with cardiovascular disease treated with either evolocumab or alirocumab. Patients were sampled for cEPCs at baseline, 1- and 3-months following initiation of PCSK9 mAb. cEPCs were assessed using flow cytometry by expression of CD34/CD133 and vascular endothelial growth factor receptor (VEGFR)-2, and functionally by formation of colony forming units (CFUs) and by Mitochondrial Tetrazolium (MTT) assay, indicative of cEPCs viability.</div></div><div><h3>Results</h3><div>51 patients (median age 67 (IQR 63,74) years;63 % male, median low-density lipoprotein-cholesterol (LDL-C) 125 (102,165) mg/dL) were initiated on PCSK9 mAb therapy (evolocumab <em>n</em> = 22, alirocumab <em>n</em> = 29) for secondary prevention. Following 3-month treatment with PCSK9 mAb, there was an increase in CD34<sup>(+)</sup>VEGFR-2<sup>(+)</sup> and CD133<sup>(+)</sup>VEGFR-2<sup>(+)</sup> levels (0.50 % [IQR 0.30,1.04] to 1.36 % [0.89, 1.73], <em>p</em> &lt; 0.001 and 0.57 % [0.25,0.88] to 1.18 % [0.74,1.66], <em>p</em> &lt; 0.001, respectively). Functionally, increase in EPCs-CFUs was evident (0.5 [0.0,1.0] to 2.0 [1.5,2.5], <em>p</em> &lt; 0.001) with concomitant increase in MTT (0.11 [0.09,0.15] to 0.17 [0.12,0.21], <em>p</em> &lt; 0.001). Stratifying by PCSK9 mAb, both agents were associated with an increase in cEPCs level and function.</div></div><div><h3>Conclusions</h3><div>In hypercholesterolemic patients with cardiovascular disease treated with PCSK9 mAb, there is an increase in cEPCs levels and function from baseline levels. These findings, which persist in both evolocumab and alirocumab, might suggest a novel pleiotropic class effect.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"20 ","pages":"Article 100896"},"PeriodicalIF":4.3000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of preventive cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666667724002642","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The role of circulating endothelial progenitor cells (cEPCs) in vascular repair and their association to cardiovascular protection is well established.

Objectives

We examined the effect of proprotein convertase subtilisin kexin type 9 monoclonal antibodies (PCSK9 mAb) on cEPCs in adults with hypercholesterolemia and cardiovascular disease, aiming to establish a pleotropic class effect.

Methods

Non-interventional prospective study in patients with cardiovascular disease treated with either evolocumab or alirocumab. Patients were sampled for cEPCs at baseline, 1- and 3-months following initiation of PCSK9 mAb. cEPCs were assessed using flow cytometry by expression of CD34/CD133 and vascular endothelial growth factor receptor (VEGFR)-2, and functionally by formation of colony forming units (CFUs) and by Mitochondrial Tetrazolium (MTT) assay, indicative of cEPCs viability.

Results

51 patients (median age 67 (IQR 63,74) years;63 % male, median low-density lipoprotein-cholesterol (LDL-C) 125 (102,165) mg/dL) were initiated on PCSK9 mAb therapy (evolocumab n = 22, alirocumab n = 29) for secondary prevention. Following 3-month treatment with PCSK9 mAb, there was an increase in CD34(+)VEGFR-2(+) and CD133(+)VEGFR-2(+) levels (0.50 % [IQR 0.30,1.04] to 1.36 % [0.89, 1.73], p < 0.001 and 0.57 % [0.25,0.88] to 1.18 % [0.74,1.66], p < 0.001, respectively). Functionally, increase in EPCs-CFUs was evident (0.5 [0.0,1.0] to 2.0 [1.5,2.5], p < 0.001) with concomitant increase in MTT (0.11 [0.09,0.15] to 0.17 [0.12,0.21], p < 0.001). Stratifying by PCSK9 mAb, both agents were associated with an increase in cEPCs level and function.

Conclusions

In hypercholesterolemic patients with cardiovascular disease treated with PCSK9 mAb, there is an increase in cEPCs levels and function from baseline levels. These findings, which persist in both evolocumab and alirocumab, might suggest a novel pleiotropic class effect.

Abstract Image

接受 PCSK9 单克隆抗体治疗的已确诊心血管疾病患者体内的循环内皮祖细胞
背景循环内皮祖细胞(cEPCs)在血管修复中的作用及其与心血管保护的关系已得到公认。我们研究了高胆固醇血症和心血管疾病成人患者中的丙蛋白转换酶亚基克星 9 型单克隆抗体(PCSK9 mAb)对 cEPCs 的影响,旨在确定其多级效应。使用流式细胞术通过 CD34/CD133 和血管内皮生长因子受体 (VEGFR)-2 的表达评估 cEPCs,并通过集落形成单位 (CFU) 的形成和线粒体四氮唑 (MTT) 试验评估 cEPCs 的功能,以显示 cEPCs 的活力。结果51名患者(中位年龄67(IQR 63,74)岁;63%为男性,中位低密度脂蛋白胆固醇(LDL-C)125(102,165)毫克/分升)开始接受PCSK9 mAb治疗(evolocumab n = 22,alirocumab n = 29),以进行二级预防。使用 PCSK9 mAb 治疗 3 个月后,CD34(+)VEGFR-2(+) 和 CD133(+)VEGFR-2(+) 水平有所提高(分别为 0.50 % [IQR 0.30,1.04] 至 1.36 % [0.89, 1.73],p < 0.001;0.57 % [0.25,0.88] 至 1.18 % [0.74, 1.66],p < 0.001)。从功能上看,EPCs-CFUs明显增加(0.5 [0.0,1.0] 到 2.0 [1.5,2.5],p <0.001),MTT也随之增加(0.11 [0.09,0.15] 到 0.17 [0.12,0.21],p <0.001)。结论在接受 PCSK9 mAb 治疗的高胆固醇血症心血管疾病患者中,cEPCs 水平和功能较基线水平均有所提高。这些发现在 evolocumab 和 alirocumab 中都持续存在,可能暗示了一种新的多效应类作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American journal of preventive cardiology
American journal of preventive cardiology Cardiology and Cardiovascular Medicine
CiteScore
6.60
自引率
0.00%
发文量
0
审稿时长
76 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信